Abstract 735P
Background
Testicular germ cell tumors (TGCT) have an excellent prognosis. This study aimed to provide population-based clinical data on cause-specific deaths with detailed treatment information, as such data are scarce.
Methods
From the Cancer Registry of Norway we identified 6167 men with testicular cancer diagnosed 1980-2009, of whom 714 died before 2011. Excluding non-TGCT, clinical or post-mortem diagnoses, 588 were included. Information on Royal Marsden clinical stage (CS), comorbidity, treatment, follow-up and cause of death was obtained from patient journals.
Results
Of 588 deceased patients, 311, 191 and 86 were diagnosed in the 1980s, 90s and 00s, respectively. Most had seminoma (55%), and 48% were concurrent smokers. Median time to death (MTD) of TGCT, treatment complications or other causes was 1.5, 0.4 and 12.1 years, respectively. Of 315 deceased patients with initial CS1, 4% died of relapsed TGCT or treatment complications, while 35% died of non-TGCT cancer. Of 273 deceased patients with initial metastatic TGCT, 149 (55%) died of TCGT or treatment complications. Most had nonseminoma (77%). The primary treatment in these 149 patients was a combination of chemotherapy and surgery in 41%, chemotherapy alone in 33%, radiotherapy alone in 3%, trimodal treatment in 11%, radiotherapy and chemotherapy in 7%, while 4% received no treatment. Of the 149 patients, 95 (64 %) had CS4: pulmonary metastases, non-pulmonary visceral metastases or both were reported in 84, 42 and 34 patients, respectively. According to IGCCCG, 61%, 27% and 4% belonged to the poor, intermediate and good prognosis groups, respectively. Most (58%) died in primary treatment before entering follow-up. Of all 273 patients, 14 % died of non-TGCT cancer.
Conclusions
In this complete three-decade cohort, cause-specific death of TGCT was exceedingly rare in CS1 or good prognosis metastatic disease. TGCT death was rare if patients went into follow-up after primary treatment. Cause-specific mortality was most pronounced in patients receiving chemotherapy following post-chemotherapy surgery, in patients with nonseminoma or with visceral metastases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Central Norway Regional Health Authority.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
844P - Progression -free survival prediction of multiple myeloma patients in five European countries using machine learning models
Presenter: Maria Luisa Pleguezuelo Witte
Session: Poster session 18
845P - A machine learning based clinical platform for cancer subtyping and data integration in hematological malignancies
Presenter: Michelle Tang
Session: Poster session 18
846P - Artificial intelligence-driven identification of onco-hematology patients who may develop severe COVID-19
Presenter: Souad Assaad
Session: Poster session 18
847P - Fatal infections among leukemia patients
Presenter: Huijie Zhou
Session: Poster session 18
848P - Mortality after rasburicase vs allopurinol anti-hyperuricemia monotherapy in patients with liquid tumors
Presenter: Mitchell Cairo
Session: Poster session 18
849P - Long non-coding RNA signatures and their role in the progression of childhood T cell acute lymphoblastic leukemia
Presenter: Pankaj Sharma
Session: Poster session 18
850P - A zebrafish model of MYC-driven acute myeloid leukemia reveals that neutrophil resistance to oncogenic transformation depends on their ability to promote PP2A-mediated MYC proteasomal degradation
Presenter: Anna Maria Luciano
Session: Poster session 18
851P - Characterization of a zebrafish model of MYC-driven acute myeloid leukemia
Presenter: Anna Maria Luciano
Session: Poster session 18
852P - c-MAF-driven metabolic reprogramming mediates H3K27 hyperacetylation to regulate super enhancer-associated genes
Presenter: Phyllis SY Chong
Session: Poster session 18
946P - Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study
Presenter: Shichun Lu
Session: Poster session 18